All News

Vardenafil HCI (Staxyn, GlaxoSmithKline, Merck, and Bayer), an orally disintegrating tablet indicated for the treatment of erectile dysfunction in men, is now available in U.S. pharmacies.

The National Community Pharmacists Association Conference taking place May 23 to May 25 in Washington, D.C., at the Hyatt Regency on Capitol Hill is focusing on how the expert medication counseling and new, nontraditional services provided by local pharmacists can help reduce costs and improve patient outcomes.

Proton pump inhibitors are associated with a 29% increased risk of fracture, including a 31% increased risk of hip fracture and a 54% increased risk of vertebral fracture, according to a study published in the May/June 2011 issue of Annals of Family Medicine.

There is no safe therapeutic window of time for using NSAIDs in patients with prior myocardial infarction. Even short-term treatment with most NSAIDs appears associated with increased risk of death and recurrent MI, reported a study published in Circulation.

The American Society of Health-System Pharmacists board of directors recently selected Paul W. Abramowitz, PharmD, FASHP, as executive vice president and CEO-designate.

For the fourth consecutive year, diabetes therapy topped the list of contributors to drug use trends in therapeutic categories, contributing 16.1% to overall growth in drug spending in 2010 due to an increasing number of patients, according to the recently released 2011 Medco Drug Trend Report, which tracks utilization and spending.

FDA has approved boceprevir (Victrelis, Merck) for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients aged 18 years and older with compensated liver disease.

The American Pharmacists Association is encouraging seniors to contact their pharmacists during Older Americans Month to gain better knowledge of the medications they are taking and to learn about available wellness opportunities.

Mississippi Governor Haley Barbour has signed into law S.B. 2445, which reauthorizes the state?s Pharmacy Practice Act and requires pharmacy benefit managers to be subject to oversight by the Mississippi Board of Pharmacy.

APhA's white paper focusing on improving REMS programs and designing a system that maximizes patient safety while minimizing burdens on the healthcare system was published in the May/June issue of the Journal of the American Pharmacists Association.

Frustrated by its lack of success at reining in drug-company abuses, FDA is bringing back a legal doctrine spawned by long-dead rodents to bring criminal charges against pharmaceutical executives, including executives who had no personal knowledge of company misdeeds.